Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces that it has co-led a CHF79 million Series B financing round in NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform.

Angelini Ventures has co-led the financing with Kurma Growth Opportunities Fund, Wellington Partners and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK and HighLight Capital, as well as existing investors. Regina Hodits, PhD, Managing Director at Angelini Ventures, will join NUCLIDIUM’s Board of Directors.

This new investment reflects Angelini Venture’s strategy of backing companies with clearly defined product profiles that address high unmet medical needs in well-defined patient populations.

The proceeds will fund the clinical development of NUCLIDIUM’s Copper-61/Copper-67 (⁶¹Cu/⁶⁷Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network.

NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. Diagnostic results from initial clinical trials in these indications show superior lesion detection and higher tumor-to-background ratios compared with clinically approved tracers. With this financing, NUCLIDIUM will continue expanding its worldwide production and manufacturing network for diagnostics and therapeutics, growing its international team and strengthening strategic collaborations with hospitals and academic centers, initially across Europe and North America.

Regina Hodits, PhD, Managing Director at Angelini Ventures said, “We are pleased to have co-led this financing in NUCLIDIUM alongside other high-quality European investors. At Angelini Ventures we continue to identify and invest in companies that pursue scientifically differentiated opportunities with a clear path to address unmet needs. We look for dynamic founders and situations where our funding and active involvement can help expand therapeutic potential.

“This investment reflects our strong conviction in the future of precision medicine and our belief in NUCLIDIUM’s potential to scale as a next-generation company. The team also brings deep radiopharmaceutical expertise and a proven track record of building high-value companies in this space.”

Leila Jaafar-Thiel, CEO and Co-founder of NUCLIDIUM added, “NUCLIDIUM is entering the next clinical phases with its lead compounds to diagnose and treat metastatic prostate, neuroendocrine tumors and breast cancer. The successful Series B financing round reflects the confidence of our investors in NUCLIDIUM’s vision and the transformative potential for the diagnostic and therapeutic industry in oncology and nuclear medicine. Their support will further enable us to accelerate the clinical development of our compounds and strengthen our commitment to innovation in precision oncology.”